Kazunori Yamanaka
Lead, Medical Bioinformatics & Translational Research Takeda Pharmaceutical
Seminars
Tuesday 19th May 2026
Serial ctDNA Monitoring to Advance Oncology Drug Development: Clinical Value, Reimbursement Barriers in Japan, & Lessons from Takeda’s mCRC Study
2:30 pm
- The importance of longitudinal ctDNA monitoring (pre-/on-treatment)
- The challenges of routine implementation under Japan’s current reimbursement framework
- Insights from our mCRC clinical study on how serial ctDNA dynamics may inform patient stratification and CDx utility
